A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product

A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product

Abstract Introduction Biosimilars need to demonstrate similarity in terms of quality, pharmacokinetics (PK), efficacy, safety, and immunogenicity. Here, we report the outcome of a comprehensive evaluation of the immunogenicity of the biosimilar BAT1806 compared with the tocilizumab reference product...

Full description

Saved in:
Bibliographic Details
Main Authors: Hans C. Ebbers, Peter C. Taylor, Xiaomei Leng, Wei Wei, Niamh M. Kinsella, Yinbo Zhou, Xiaolei Yang, Paul Chamberlain
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-04-01
Series:Rheumatology and Therapy
Subjects:
Antibodies
Arthritis
Rheumatoid
Biosimilar pharmaceuticals
Online Access:https://doi.org/10.1007/s40744-025-00760-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40744-025-00760-y

Similar Items